Investigational Therapy RHB-107 Holds Potential to Treat IBD, Other Disorders, RedHill Announces

Investigational Therapy RHB-107 Holds Potential to Treat IBD, Other Disorders, RedHill Announces
RedHill Biopharma is evaluating the potential of its proprietary therapy RHB-107 (upamostat, formerly known as Mesupron) to treat inflammatory digestive diseases and cancer, the company announced in a press release. Results of experimental studies show that WX-UK1, the active compound in RHB-107, efficiently inhibits five serine proteases called trypsin-3, trypsin-2, trypsin-1, matriptase-1, and trypsin-6. These enzymes are associated with cancer progression and spreading, and are also important mediators of several mechanisms involved in gut homeostasis, or stablity. These findings will be presented at the American Association for Cancer Research (AACR) 2018 Annual Meeting April 14-18 in Chicago. The study, “New potential therapeutic applications of WX-UK1, as a specific and potent inhibitor of human trypsin-like proteases,” is the result of a collaboration between RedHill and researchers at Aarhus University in Denmark. RHB-107 was initially developed to target the serine protease urokinase (uPA), which is involved in a tissue remodeling process related to tumor invasion and spreading. Supported by its initial anti-cancer profile, the U.S. Food and Drug Administration (FDA) granted
Subscribe or to access all post and page content.